Pharmaceutical quality control: Connecting with your supply chain!

Patient recruitment is arguably one of the most important aspects of a clinical trial. Without enough participants, trials will inevitably fail, meaning potentially effective therapies will not be brought to market.

In this exclusive Drug Digest video interview, Meg Rivers and Feliza Mirasol, Pharmaceutical Technology editors, discuss the benefits of automating entire workflows in analytics versus automating only specific pieces of equipment or only certain processes with Nick Pattinson, head of product, Automata.

In this webinar, Dr. Xu will summarize recent data on inherited risk for prostate cancer, including germline mutations in high-penetrance genes (HPGs), risk-associated SNPs, and SNP-based genetic risk score (GRS). He will present detailed data supporting the broad-sense validity of GRS in risk assessment as well as the need for assessing the narrow-sense validity of GRS values. Finally, he will review the data supporting the importance of GRS when estimating the penetrance of HPGs.

Various neurodegenerative processes result in the development of diseases like Alzheimer’s (AD), Parkinson’s (PD), amyotrophic lateral sclerosis (ALS), and, arguably, multiple sclerosis (MS). Despite years of research, drug discovery initiatives, and promising clinical trials, these diseases remain incurable. But recent studies have suggested common mechanisms underlying these pathologies. Atypical protein assembly resulting in plaque formation is a common pathological finding in both AD and PD, while neuronal death is a primary (ALS) or secondary (MS) hallmark of the disease. For a detailed look at the mechanisms that drive an array of neurodegenerative diseases, The Scientist is bringing together a panel of experts to share their research, discuss current therapeutic approaches, and offer their insights. Come engage with our panel and get the answers you seek.